CompletedPhase 1NCT03186677

Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients

Studying Hemophilia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
ISU Abxis Co., Ltd.
Principal Investigator
ChurWoo You, PhD
Eulji University Hospital Seo-gu
Intervention
ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg(biological)
Enrollment
11 enrolled
Eligibility
12-65 years · All sexes
Timeline
2017 – 2019

Study locations (3)

Collaborators

Catalyst Biosciences

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03186677 on ClinicalTrials.gov

Other trials for Hemophilia

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia →

← Back to all trials